HLB Life Science Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
171
- Stock Symbol
-
067630
- Investments
-
4
- Share Price
-
$4.61
- (As of Thursday Closing)
HLB Life Science General Information
Description
HLB Life Science Co Ltd is engaged in the energy services and renewable energy businesses. It offers energy-saving facilities, condensing water recovery systems, cogeneration systems, and solar energy development systems. In addition to the existing energy business, the firm is also engaged in investing in new drug development and medical-related field.
Contact Information
Website
www.hlb-ls.comCorporate Office
- 51-9, Dongtan Advanced Industry 1-ro
- 8th floor, Yeongcheon-dong, M Tower Knowledge Industry Center
- Hwaseong, Gyeonggi-do
- South Korea
Corporate Office
- 51-9, Dongtan Advanced Industry 1-ro
- 8th floor, Yeongcheon-dong, M Tower Knowledge Industry Center
- Hwaseong, Gyeonggi-do
- South Korea
HLB Life Science Stock Performance
As of 27-Mar-2025, HLB Life Science’s stock price is $4.61. Its current market cap is $547M with 119M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.61 | $4.54 | $4.08 - $15.49 | $547M | 119M | 1.01M | $0.04 |
HLB Life Science Financials Summary
As of 31-Dec-2024, HLB Life Science has a trailing 12-month revenue of $74.9M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 836,392 | 836,392 | 974,539 | 821,596 |
| Revenue | 74,932 | 74,932 | 74,948 | 77,076 |
| EBITDA | 17,618 | 17,618 | 16,486 | (36,328) |
| Net Income | 4,498 | 4,498 | (4,576) | (42,007) |
| Total Assets | 365,939 | 365,939 | 328,631 | 326,065 |
| Total Debt | 84,036 | 84,036 | 129,262 | 116,773 |
HLB Life Science Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
HLB Life Science Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
HLB Life Science Patents
HLB Life Science Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210100487-A1 | Unit for collecting and ejecting blood | Active | 04-Oct-2019 | ||
| US-12201423-B2 | Unit for collecting and ejecting blood | Active | 04-Oct-2019 | ||
| US-20200330013-A1 | Unit for collecting blood | Inactive | 22-Apr-2019 | ||
| US-20190353432-A1 | Apparatus for filling heat storage material | Inactive | 18-May-2018 | F28D20/021 |
HLB Life Science Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
HLB Life Science Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
HLB Life Science Acquisitions (4)
HLB Life Science’s most recent deal was a Merger/Acquisition with Tinico for . The deal was made on 10-Jan-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tinico | 10-Jan-2025 | Merger/Acquisition | Other Commercial Products | ||
| Hwajin Medical | 21-Feb-2018 | Merger/Acquisition | Medical Supplies | ||
| Shinwha Advance Company | 05-Aug-2016 | Merger/Acquisition | Distributors (Healthcare) | ||
| From2 Information & Communications | 01-Apr-2014 | Merger/Acquisition | Wireless Communications Equipment |
HLB Life Science ESG
Risk Overview
Risk Rating
Updated September, 27, 2023
22.1 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Healthcare
Industry
of 581
Rank
Percentile
Medical Distribution
Subindustry
of 48
Rank
Percentile
HLB Life Science Exits (1)
HLB Life Science’s most recent exit was on 01-Apr-2014 from From2 Information & Communications. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| From2 Information & Communications | 01-Apr-2014 | Completed |
|
HLB Life Science Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Tinico | Cheongju-si, South Korea | 2011 | |
| Hwajin Medical | Cheonan-si, South Korea | 1993 |
HLB Life Science FAQs
-
When was HLB Life Science founded?
HLB Life Science was founded in 1998.
-
Where is HLB Life Science headquartered?
HLB Life Science is headquartered in Hwaseong, South Korea.
-
What is the size of HLB Life Science?
HLB Life Science has 171 total employees.
-
What industry is HLB Life Science in?
HLB Life Science’s primary industry is Drug Discovery.
-
Is HLB Life Science a private or public company?
HLB Life Science is a Public company.
-
What is HLB Life Science’s stock symbol?
The ticker symbol for HLB Life Science is 067630.
-
What is the current stock price of HLB Life Science?
As of 27-Mar-2025 the stock price of HLB Life Science is $4.61.
-
What is the current market cap of HLB Life Science?
The current market capitalization of HLB Life Science is $547M.
-
What is HLB Life Science’s current revenue?
The trailing twelve month revenue for HLB Life Science is $74.9M.
-
What is HLB Life Science’s annual earnings per share (EPS)?
HLB Life Science’s EPS for 12 months was $0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
